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Chih-Zen Chang1,2,3*, Shu-Chuan Wu2, Chih-Lung Lin1,2 and Aij-Lie Kwan1,2Abstract
Background: Up-regulation of regulated upon activation, normal T-cell expressed and secreted (RANTES/CCL5) and
adhesion molecules is observed in the serum of animals following experimental subarachnoid hemorrhage (SAH).
The present study was to examine the effect of valproic acid (VPA) on RANTES and alternation of adhesion molecules
in this model.
Methods: A rodent SAH model was employed. Animals were randomly assigned into six groups. Basilar artery (BA) was
harvested for intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule–1 (VCAM-1), and E-selectin
evaluation (western blotting) and RANTES (rt-PCR). 1 ng CCL5 recombinant protein intrathecal injection was performed
in the VPA + SAH groups. (N = 5).
Results: Convoluted internal elastic lamina, distorted endothelial wall, and smooth muscle micro-necrosis was
prominently observed in the SAH groups, which is absent in the VPA treatment and the healthy controls. Treatment
with VPA dose-dependently reduced the ICAM-1, E-selectin and RANTES level, compared with the SAH group (p <0.01).
The administration of CCL5 significantly increased CD45(+) glia and ICAM-1 level in the VPA treatment groups.
Conclusion: VPA exerts its anti-vasospastic effect through the dual effect of inhibiting RANTES expression and reduced
adhesion molecules. Besides, VPA also decreased CD45(+) cells transmigrated to the vascular wall. The administration
of CCL5 significantly reversed the inhibitory effect of this compound on CD45(+) monocytes, E-selectin, and ICAM-1
level. This study also lends credence to support this compound could attenuate SAH induced adhesion molecules and
neuro-inflammation in a CCL5 dependent mechanism.
Keywords: Chemokine ligand 5, Intercellular adhesion molecule–1, Subarachnoid hemorrhage, Vasospasm, Vascular
cell adhesion molecule–1, Valproic acidBackground
Delayed neurological deficit, and acute cerebral ischemia
associated with subarachnoid hemorrhage (SAH) in-
duced vasospasm persists to be a major cause of mortal-
ity and disability in patients suffered from ruptured
aneurysm [1-4]. Owing to the lack of adequate medical
treatment for this condition, it prompts many pre-* Correspondence: changchihzen2002@yahoo.com.tw
1Department of Surgery, Faculty of Medicine, School of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan
2Division of Neurosurgery, Department of Surgery, Kaohsiung Medical
University Hospital, No.100, Tzyou 1st Road, Kaohsiung, Taiwan
Full list of author information is available at the end of the article
© 2015 Chang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.clinical and clinical studies of the disease content [5-7].
There is a mounting body of both direct and circum-
stantial evidence that spasmogenic substances or ligands
are critical in the development and maintenance of cere-
bral vasospasm. Basic molecular and cellular research
also implicates two major hypotheses as key points to
cerebral vasospasm. One hypothesis centers on the syn-
ergic roles of nitric oxide, a potent vasodilator, nitric
oxide synthase and endothelin-1, a strong endogenous
vaso-constrictor, all released form endothelial cells once
SAH happened [8-13], and the other focuses on intra-
cellular signal transduction [4,5,9,14-21]. The putativeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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emphasized, even its role in the genesis of cerebral vaso-
spasm has been recognized. Till now, various inflamma-
tory constituents, including adhesion molecules, cytokines,
leukocytes, immunoglobulins, and complements, were ob-
served in the pathogenesis of SAH induced brain injury
and delayed cerebral vasospasm [9,11,18,22-28].
The blood clot and its by-product, existed in the sub-
arachnoid space, are able to induce innate and delayed
sterile inflammation, which mediates subsequent acute
arteries and arteriolar constriction, passive venous oblit-
eration and delayed arterial spasm [21]. However, the
benefits of inflammation development after SAH re-
mains unclear. CC chemokine ligand-5 (CCL5), or regu-
lated on activation, normal T-cell expressed, and secreted
(RANTES), is expressed by cell types such as T-cells, fi-
broblasts, and mesangial cells [22]. Through interacting
with specific chemokine receptors (CCR1, CCR3, CCR4,
and CCR5) [17,29-32], RANTES is able to mediate mono-
cytes and T-cells transmigration into the vascular intima
[17,33]. Glass et al. demonstrated monoclonal antibody
for CCL5 was able to diminish leukocyte infiltration into
the central nervous system and reduced neurologic deficit
in a multiple sclerosis mice [30,31]. It may be reasonable
to postulate that RANTES is involved in inflammation in
the brain and plays a putative role in SAH induced vaso-
constriction.
It is well known that leukocyte migration into the
endothelium of postcapillary venous was mediated by a
cascade of events initiated by the selectin family of adhe-
sion molecules [5,14,23,34]. The adhesion glycoproteins
family, including intercellular adhesion molecule-1 (ICAM-
1), vascular CAM-1 (VCAM-1) and E-selectins, plays a
major role in the formation of firm adhesion and transen-
dothelial migration of leucocytes into inflamed vessels.
Both ICAM-1 and VCAM-1 are expressed on cerebral vas-
cular endothelial cell lines derived from the human, and
can be up-regulated by pro-inflammatory cytokines, such
as tumor necrosis factor alpha (TNF-α) or interleukin-1
(IL-1), involving activation of nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB) and activator protein
1 (AP-1) [14,35,36].
Valproic acid (VPA, 2-propylpentanoic acid), a histone
deacetylase (HDAC) inhibitor, is widely used in the
treatment of epilepsy [37-39]. In addition to its anti-
epilepsy effects, VPA has been shown to mediate neuro-
protection through the activation of signal transduction
pathways, such as the extracellular signal-regulated kin-
ase (ERK) pathway and through inhibiting proapoptotic
factors [40]. Like other HDAC inhibitors, VPA has been
shown to inhibit histone deacetylases and leads to the
accumulation of acetylated histones and acetylated proteins,
which is crucial for the regulation of gene expression
by chromatin remodeling [11,37,41,42]. Recent studieswere focused on its chronic inflammatory effect in
sporadic amyotrophic lateral sclerosis, Alzeimer’s disease,
Huntington’s disease and Parkinson’s disease [43,44].
Taking these findings together, we propose that VPA,
with its unique property in gene expression, may be ef-
fective in SAH-induced inflammation and vasospasm.
Given the importance of arterial lesion formation and
the various effects of pro-inflammatory cytokines stimu-
lation on leukocyte and endothelial dysfunction, the rat
SAH model was used to test the hypothesis that VPA
can attenuate RANTES associated late onset inflammation
following experimental SAH. The suppression of adhesion
molecules can partly attribute to its inhibitory effect on
the following systemic immunity subsequent to SAH.
Methods
Materials
Valproic acid (VPA) is characterized as a potent inhibi-
tor of histone deacetylases and was bought from the
Sigma-Aldrich China Inc. Shanghai 20031, China. Poly-
clonal anti-rat intercellular adhesion molecule-1 (ICAM-
1, MBS246106), vascular CAM-1 (VCAM-1, MBS190465)
and E-selectins (MBS343017) antibody were obtained
from MyBioSource, Inc. San Diego, CA 92195–3308,
USA. Recombinant CC chemokine ligand-5 (CCL5), or
regulated on activation, normal T-cell expressed, and se-
creted (RANTES, MBS143280) protein was purchased
from MyBioSource, Inc. San Diego, CA 92195–3308,
USA. CNM protein extraction kits were from Biochain
(K3012010, Hayward, CA 94545, USA). An osmotic mini-
pump was bought form Alzet corp, Palo Alto, CA 94306,
USA. VPA was prepared by Ms. Wu SC (Kaohsiung
Medical University Hospital, Kaohsiung 807, Taiwan),
and phosphate-buffered saline (PBS, bought from Sigma-
Aldrich China Inc. Shanghai 20031, China) was used
as a vehicle.
Induction of experimental SAH
Fifty four male Sprague–Dawley rats (n = 9), weighing
between 300–400 g (purchased from the BioLasco
Taiwan Co., Ltd., authorized by Charles River Lab), were
used in this study. All experimental protocols were ap-
proved and supervised by the University of Kaohsiung
Medicine Animal Research Committee and in accord-
ance with the Declaration of Helsinki (1964). The rats
received anesthesia by an intraperitoneal injection of a
mixture of 0.9 mg/100 gm xylazine and 5.5 mg/100 gm
KetaVed. 1 ml/kg body weight (BW) fresh arterial blood
was withdrawn from tail artery and injected into the
craniocervical junction using a stereotactic apparatus
(Stoelting, Wood Dale, IL 60191, USA) [45]. No mortal-
ity was found during the study. After the induction, ani-
mals were placed in ventral recumbent position for
30 minutes to let ventral blood clot formation. The
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duction. After monitoring for respiratory distress and
giving mechanical ventilation if necessary, the animals
were returned to the vivarium till fully awake. A habitat
was offered with a 12 h light–dark cycle and an access
to food and water ad lib.
General design of experiments and treatment groups
The animals were randomly divided into the following
groups (9 rats/group): 1) sham operated (no SAH); 2)
SAH only; 3) SAH plus vehicle; SAH rats receiving VPA
treatment of 4) 10 mg/kg/day, 5) 20 mg/kg/day and 6)
40 mg/kg/day. Treatment group was defined as animals
received VPA administration 1 h after the induction of
SAH. The dosage was adjusted according to our pilot
study, devoid of hepatic and renal toxicity. The first ad-
ministration of VPA was intraperitoneal injection at 1 h
after induction of SAH and then by using an osmotic
mini-pump (Alzet corp, Palo Alto, CA 94306, USA). PBS
was used a vehicle. After re-anesthesia, CSF sampling
from each animal was obtained through a 30-gauge nee-
dle into the foramen magnus by using stereotactic ap-
paratus (Stoelting, Wood Dale, IL 60191, USA). The
animals were sacrificed by perfusion–fixation 72 h after
2nd SAH. Cortical tissue homogenates were obtained by
means of placing a 22-gauge needle inserted, 3 mm in
depth, into the skull bone (N = 5) through a burr hole
craniectomy (2 mm apart from the bregma). To test the
neuro-inflammatory effect of VPA, another experiment
was carried out in the the 40 mg/kg/day VPA + SAH
group with 7) 1 ng CCL5 recombinant protein intra-
thecal injection or 8) not (5 animals each group). The
tissues were frozen instantly and cut into 25 μm-thick sec-
tions (Reichert-Jung Ultracut E ultramicrotome). They were
then stained with hematoxylin and eosin for video-assisted
microscopy and the analysis of BA cross-sectional area.
Perfusion–fixation
At the end of experiment, the rats were anesthetized by
administration of 7 mg/kg Zoletil 50 (a mixture of tileta-
mine hypochloride and zolazepam hypochloride. VIR-
BAC, L.I.D., 06516 Carros, France). The femoral artery
was catheterized to obtain blood samples for arterial
blood gas, Na+, K+, glutamate oxaloacetate transaminase
(GOT), glutamate pyruvate transaminase (GPT), blood
urea nitrogen (BUN), Creatinine (Cr) levels evaluation.
Via opening the thorax, the left ventricle was canalled
with a NO16 catheter with the descending aorta clamped,
and the right atrium opened. 100 mL of 70 mm Hg of
0.01 M phosphate buffer (pH 7.4) was under perfusion,
followed by fixation with 160 mL 2% paraformaldehyde in
the PBS solution at 36°C under a perfusion pressure of
100 mm Hg. The harvested brain was immersed in a fixa-
tive at 4°C overnight. Formed subarachnoid clots coveredthe basilar artery (BA) was inspected in all SAH animals
visually.
Hemodynamic measurements
By using a tail-cuff method (SC1000 Single Channel Sys-
tem, Hatteras Instruments, NC, 27518, USA) and rectal
thermometer (BIO-BRET-2-ISO. FL 33780, USA), heart
rate, blood pressure, and rectal temperature of the rats
were monitored before and after VPA treatment as well
as at interval of 12 h after SAH.
Neurological assessment
A modified limb-placing tests (MLPT) [42], comprised
two parts: ambulation and placing/stepping reflex exam-
inations were performed to examine the forelimb and
hind-limb activity before and after animals subject to
SAH, were used to evaluate the behavior change of rats
before and at 24 h after the induction of SAH. The final
index was the sum of the scores of walking with lower
extremities and placing/stepping reflex. A motor deficit
index (MDI) was calculated for each rat at each time
interval. MDI score more than three were considered to
be paraplegic, whereas MDI score less than three were
considered neurological deficit.
Tissue morphometric studies of basilar artery (BA)
Five selected cross-sections from the BA of each animal
were randomly analyzed by two investigators blinded to
the treatment groups. Automated measurements of the
luminal cross-sectional area were made using computer-
assisted morphometry (Image 1, Universal Imaging Corp.
Downingtown, PA 19335, USA). Areas of five cross-
sections from a given animal were averaged to provide a
single value for each animal. Group data are expressed as
the means ± standard deviation of the means.
Immunostaining of microglia and astrocytes with CD45
antibodies
Video-assisted microscope (x 400, DSX500, Yuan Li
Instrument Co., Ltd. 114 Taipei, Taiwan. authorized by
Olympus Scientific Solutions Americas Inc. MA 02453,
USA) was used to identify CD45 positive microglia and
astrocytes. Isolated rat BAs were under perfusion and
fixation with 4% paraformaldehyde. Coronal sections of
the BAs were stored overnight on slides at −80°С in ac-
cordance with the supplier’s instructions. Mouse anti-rat
CD45 monoclonal antibody (Thermo Fisher Scientific Inc.
Waltham, MA 02451, USA) was used at a dilution of
1:1000, and immunostaining was performed for 40 min at
25°С and let dry overnight as described in the mouse
monoclonal alkaline phosphatase anti-alkaline phosphat-
ase (APAAP) technique [43,46]. Five consecutive sections
of each rat were photographed, and the CD45 positive
cells were measured.
Table 1 Modified limb-placing test (MLPT)
Group Treatment Ambulation Placing/stepping
reflex
MDI
Sham-operated 0 0 0
SAH 1.44 ± 0.42 1.42 ± 0.12 2.86 ± 0.36
SAH+ Vehicle 1.40 ± 0.20 1.42 ± 0.21 2.82 ± 0.41
SAH+ Valproic acid
10 mg/kg 1.14 ± 0.24 0.84 ± 0.15 1.98 ± 0.39
20 mg/kg 1.16 ± 0.33 0.72 ± 0.25* 1.88 ± 0.58
40 mg/kg 0.50 ± 0.25* 0.52 ± 0.24* 1.02 ± 0.48*
Results are expressed as the mean ± SEM, n = 9; *: p < 0.01 versus SAH condition
by Mann-Whitney U test.
Figure 1 Comparison of lumen cross-sectional areas of the basilar art
artery obtained from the sham operated rat (A), SAH only animals (B), the veh
(VPA) (D), 20 mg/kg/day VPA treatment SAH rats (E) and 40 mg/kg/day VPA
quantification of the lumen cross-sectional areas. All values are mean ± SD
the vasospastic response when compared with the vehicle + SAH group. *
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and RANTES
The BA homogenates concentrations of ICAM-1, VCAM-
1, E-selectin, RANTES by using commercially available
enzyme-linked immunosorbent assay kits (SOMA Acous-
tic Co., Ltd. Chung Hsiao E. Road, 10655 Taipei, Taiwan
distributed by R&D Systems) as stated by the supplier’s
instructions. Samples containing 30 μg of protein was
stirred with LDS sample buffer (contains 40% glycerol, 4%
lithium dodecyl sulfate (LDS), 0.8 M triethanolamine-Cl
pH 7.6, 4% Ficoll®-400, 0.025% phenol red, 0.025% coo-
massie G250, 2 mM EDTA disodium, NuPAGE® LDS
Sample Buffer (4×) NP0007; Invitrogen, Carlsbad, CA
92008, USA) and then obtained after loaded for 8%
sodiumdodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and then separated after centrifuged at
12,000 rpm for 10 min. The sampling was mounted ontoery. Top panel: representative micrographs of the cross-section of basilar
icle-treated SAH rats (C), SAH rat treated with 10 mg/kg/day valproic acid
treatment in SAH animals (F). Standard bar = 200 μm. Bottom panel:
(n = 9). Valproic acid, in 40 mg/kg/day, exerted a potential to alleviate
, **, ***: P < 0.01 compared with the SAH group.
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blocking buffer (5% non-fat dry milk in Tris-buffered sa-
line with 0.2% Tween 20) at room temperature. Rabbit
anti-rat sICAM, sVCAM, sE-selectin and RANTES poly-
clonal antibodies (1:1000, MyBioSource, Inc. San Diego,
CA 92195–3308, USA) were coated on the walls of
micro-titer plate wells. A secondary antibody conju-
gated with horseradish peroxidase (HRP) in TBS-t at
room temperature for 1 hr. Optical densities were mea-
sured by an enhanced Pierce chemiluminescent image
analyzer (a GS-700 digital densitometer, GMI, Ramsey,
MN 55303, USA).
Statistical analysis
Data are expressed as the means ± standard deviation.
For group comparisons, all statistical analyses were de-
termined with the Mann–Whitney U test (Table 1), one-
way analysis of variance (ANOVA), and the BonferroniFigure 2 Bar graph depicting VPA on the change of CD45 positive m
the induction of SAH. Toppanel revealed the sham-operated animals (A),
Treatment with 40 mg/kg/day VPA in the SAH animals (D). Lower panel re
the figure are presented as mean ± SD (n = 9). *: P < 0.01, and #, ##: P > 0.01post hoc test (Figures 1, 2, 3, 4, 5 and 6). Difference, at a
probability value less than 0.01, was considered significant.
Results
General observation
By the end of the study, there were no significant differ-
ences in the physiological parameters recorded, includ-
ing GOT, GPT, BUN, Cr, pH, blood pressure and arterial
blood gas analysis among all experimental groups. It
proved that VPA in the selected dosage has a number of
pleiotropic effects, devoid of hepatic and renal toxicity.
Grossly, the animals in the SAH only and SAH plus ve-
hicle groups revealed withdrawal behaviors, direction
disorientation, and decreased appetite.
Neurological deficit
A summary score of MLPT in the SAH groups were sig-
nificantly higher than the healthy controls and VPAonocytes or microglia infiltrating in the wall of basilar artery after
the SAH group (B), 10 mg/kg/day VPA treatment in SAH rats (C) and
vealed the CD45(+) cell count among the experimental groups. Data in
when compared with the SAH group.
Figure 3 Bar graph demonstrating valproic acid (VPA) on the expression of ICAM-1, VCAM-1 and E-selectin protein (western blot). Top
panel represents SAH only animals (A), the vehicle-treated SAH rats (B), SAH rat treated with 10 mg/kg/day valproic acid (C), 20 mg/kg/day VPA
treatment SAH rats (D) and 40 mg/kg/day VPA treatment in SAH animals (E). VPA is able to decrease the expression of ICAM-1 (at a high dose),
and E-selectin (at a high dose), but does not decrease SAH induced VCAM-1 expression. The ICAM-1, VCAM-1 and E-selectin expression in the
SAH group was set at 100%. All values are mean ± SD. *: P < 0.01, and #, ##, ###: P > 0.01, compared with the SAH group.
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hicle groups were 2.86 ± 0.36 and 2.82 ± 0.41, respect-
ively, compared with a score of 0 and 1.02 ± 0.48 in
the healthy control and 40 mg/kg VPA, respectively.
Treatment with VPA significantly improved the MDI in
the SAH groups (Table 1). Likewise, paraplegia rate (de-
fined as MDI ≥ 3 in each group) was substantially de-
creased in the VPA treatment groups when compared
with the SAH animals.
Cross-sectional areas of BAs
The cross-sectional areas of BAs in SAH rats were signifi-
cantly reduced (Figure 1). The mean cross-sectional areas
of BAs in the SAH only and SAH plus vehicle groups were
reduced by 56 and 53%, respectively, when compared with
the control group. VPA dose-dependently reduced the
mean cross-sectional area in those animals was similar tothat in controls (p > 0.01; Figure 1). The protective effect
of 40 mg/kg VPA achieved statistical significance when
a comparison was made with the SAH only or SAH plus
vehicle group (p < 0.01).
Immunostaining of microglia and monocytes with CD45
antibodies
CD45(+) astrocytes and monocytes infiltrating into the
adventia are esteemed as a sign of chronic inflammation.
Significant immunostaining of CD45 (LCA) cells was
observed in the vascular wall of the SAH and vehicle-
treatment SAH group (Figure 2). The CD45(+) cell num-
ber was counted 1.2 ± 0.5, 8.3 ± 1.4, 7.8 ± 2.3, 7.4 ± 2.6,
6.8 ± 3.1 and 4.3 ± 2.4 in the sham-operated, SAH, SAH+
vehicle, 10 mg/kg VPA + SAH, 20 mg/kg VPA treatment
SAH and 40 mg/kg VPA + SAH groups, respectively.
(p < 0.01, Figure 2, bottom panel). CD45(+) cells infiltration
Figure 4 Level of expressed RANTES in the SAH rats receiving VPA treatment (western blotting). Lower panel: left column bar graph
revealed the adhesion molecules level in the 48 h after the induction of SAH; right column revealed the RANTES activation was late-onset
inflammatory reaction, which was significantly reduced in the 40 mg/kg/day VPA treatment by the end of double shot SAH study. All groups are
identical to those shown in the legend of Figure 3. Data are showed as mean ± SD. (*: P < 0.01, and #, ##,###: P > 0.01).
Chang et al. Journal of Inflammation  (2015) 12:27 Page 7 of 11into vascular wall were increased in the CCL5 administra-
tion in 40 mg/kg/day VPA treatment SAH group (P < 0.01,
Figure 5, left column).
The expression of ICAM-1, VCAM-1, and E-selectin
protein
To evaluate the leukocyte transmembrane migration into
brain blood barrier and its facilitating protein in animals
subjected to SAH, western blotting was used to examine
ICAM-1, VCAM-1 and E-selectin. Upregulation of
VCAM-1 levels in animals after the induction of SAH,
no significant difference was observed among the SAH,
SHA and vehicle and 10 mg/kg, 20 mg/kg and 40 mg/kg
VPA plus SAH groups (Figure 3). Treatment with
40 mg/kg VPA significantly decreased the levels of E-
selectin after SAH (p < 0.01) when compared with that
of SAH plus vehicle group. Levels of ICAM-1 in the
SAH only and SAH plus vehicle groups were elevatedwhen compared with that of the control group and high
dose VPA treatment SAH group (Figure 3, p < 0.01). In
this study, VPA significantly reduced the level of E-
selectin (at a high dose) and ICAM-1 (at a high dose),
when compared with that of SAH group (Figure 3,
p <0.01). Intrathecal administration CCL5 significant
induced the suppression effect of VPA on ICAM-1
levels (Figure 6, P > 0.01).
RANTES expression
RANTES was demonstrated to play a pivotal role in the
onset of neuro-inflammation. The expression of RANTES
protein was significantly induced in the SAH groups (SAH
only, treatment with vehicle, 10 mg/kg and 20 mg/kg
VPA) when compared with the normal controls (Figure 4.
p < 0.01). VPA (at high dose) significantly decreased
RANTES expression when compared with the SAH
groups (P <0.01).
Figure 5 The effect of CCL5 on CD45(+) cells (western blot). Upper panel: immune-staining with CD45 monoclonal antibody. SAH animals
received 40 mg/kg/day VPA treatment (A) and both 1 ng CCL5 intra-thecal treatment and 40 mg/kg/day VPA treatment (B). CCL5 administration
increased the CD45(+) cell transmembranous migration into the wall of basilar artery. N = 5. Data in the figure are presented as mean ± SD.
(*,**: P < 0.01, #:P > 0.01, indicates comparison between SAH rats treatment with 40 mg/kg/day VPA or not, respectively).
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In this SAH study, VPA, a HDAC inhibitor, has shown to
be able to attenuate SAH induced chronic inflammation.
VPA were demonstrated as a novel class of potentially
therapeutic agents in the treatment of epileptic seizures
and bipolar disorder [38,42,43]. In the study of spinal cord
injury, VPA was proved to be able to promote the prolifer-
ation and differentiation of endogenous and exogenous
neural stem cell, which leads to the restoration of hind
limb function and axonal remodeling [32,39]. In Shein
et al’s study, VPA treatment significant reduced cerebral
infarct volume, suppressed microglial activation and
inhibited inflammatory markers in a permanent middle
cerebral artery infarct [40]. In vitro, VPA was demon-
strated to attenuate the secretion of TNF-α and IFN-γ
from reactive helper T cells and monocytes in the ap-
pearance of lipopolysaccharide (LPS) [42,44]. Although
the relationship between HDAC inhibitor and its protect-
ive effects remains unclear, VPA has a potent effect on theneuro-inflammation cannot be over-emphasized. A large
number of in vitro and in vivo studies have revealed that
HDAC inhibitor has a potent ability to stimulate neurite
growth in primary cultured hippocampal neurons as well
as promote axonal regeneration in animal models. By up-
regulating glial cell-derived neurotrophic factor (GDNF)
and brain-derived neurotrophic factor (BDNF) gene tran-
scription in astrocyte and glioma cells located in pre-
frontal cortex, VPA exerts neuroprotective effect in case
of CNS insults [40]. In this study, VPA was proved to be
able to suppress ICAM-1(dose-dependently) and E-selecin
(at high dose), which initiated the transmemebrane migra-
tion of leukocytes; by the way, activated RANTES protein
level was reduced in the 40 mg/kg/day VPA treatment
SAH group.
Leukocyte common antigen (LCA), also known as CD45,
belongs to a family of five glycoproteins (MW 180–240 kD)
which present on the surface of most T-lymphocytes [46].
The mouse anti-rat CD45 immunoglobulin was employed
Figure 6 Level of expressed adhesion molecules in the SAH rats receiving VPA and CCL5 treatment (western blotting). Upper panel: SAH rats
(A), SAH animals received 40 mg/kg/day VPA treatment (B) and both 1 ng CCL5 intra-thecal treatment and 40 mg/kg/day VPA treatment (C). Bar graph
revealed CCL5 reversed the effect of 40 mg/kg/day VPA on adhesion molecules. Data are showed as mean ± SD. (*: P < 0.01, and #, ##: P > 0.01).
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can also be perceived with anti-LCA antibodies. In this
study, the expression of LCA surface marker gathered at
the muscular layer of BA in the SAH rats [47]. Treatment
with 40 mg/kg/day VPA significantly reduced CD45(+)
lymphocytes and microglia in the SAH induced chronic
vasospasm, which indicates VPA, at a selected dosage, is
able to alleviate T-cell related chronic inflammation at
the cellular basis.
Our previous study revealed increased adhesion mole-
cules and pro-inflammatory cytokine in cerebrospinal
fluid (CSF) after experimental aneurysmal SAH [14].
However, the relationships among the development of
inflammatory response, vascular constriction, and de-
layed cerebral ischemia in the brain after SAH need to
be clarified. In the initial of SAH, the up-regulation of
ET-1 peaks 3–4 days after SAH followed by a negative
feedback through activation of endothelial nitric oxide
synthetase (eNOs) depletes NO, which mediated a Na+-K+
channel and further resulted in vasodilation [11,17]. Bow-
man et al. reported a polyclonal IL-6 antibody was able to
alleviate vasoconstriction in a femoral artery SAH study
[1]. The cumulative evidences support that the surge of
pro-inflammatory cytokines is antecedent to radiographic
vasospasm (peak at 4th to 14th days after SAH), and at-
tenuation of cytokines tends to minimize vascular con-
striction and reduced cerebral ischemia [4]. The
selectins, belong to transmembrane glycoproteins, areexpressed on activated vascular endothelium (E-selectin),
activated platelets (P-selectin), and leukocytes (L-selectin),
and modulate the early adhesion interactions between
endothelium and circulating neutrophils [34]. Some
studies elicit elevation of levels of E-selectin, ICAM-1,
and VCAM-1 in the CSF of patients after aneurysmal
SAH, and E-selectin levels were severely elevated in pa-
tients with moderate or severe vasospasm [10,21,27,36]. In
this study, we have found E-selectin levels to be increased
in animals subjected to SAH compared with control ani-
mals. High dose VPA significantly reduced the production
of E-selectin after SAH in this study.
Among the adhesion molecules, members of the
immunoglobulin-like superfamily (ICAM-1, −2, −3,
VCAM-1, and PECAM) have been found elevated in
SAH-induced vasospasm in both animal and human
studies [14]. Increased ICAM-1, expressed in the endothe-
lial layer and the medial layer of the BAs, are correspondent
to the severity and timing of vasospasm in experimental
SAH in rats [48]. In a rat femoral artery vasospasm study,
intraperitoneal administration of ICAM monoclonal anti-
body significantly decreased the degree of vasospasm and
the number of infiltrating leukocytes [27]. Furthermore,
administration of a monoclonal antibody against CD11
and CD18, the integrins that interact with ICAM-1, pre-
vented vasospasm in a primate model of vasospasm [36].
Lorenz et al. declared CD45 molecule induces homotypic
adhesion of human thymocytes through a ICAM-1-
Chang et al. Journal of Inflammation  (2015) 12:27 Page 10 of 11dependent pathway [49]. In this study, treatment with high
dose VPA significantly attenuates ICAM-1 and E-selectin
in the cortical homogenates of SAH rats, which corre-
sponds to the decreased CD45(+) cells present in the vascu-
lar wall of BAs.
Known as regulated on activation, normal T-cell
expressed, and secreted (RANTES), CC chemokine
ligand-5 is expressed by T-cells, fibroblasts, and
mesangial cells and stored in the α-granules of plate-
lets [35]. Once activated, RANTES is deposited onto
endothelium and responds to mediate monocytes and
T-cells transmigration into the intima [48]. As a T-
cell mitogen and mediators of pro-inflammatory cyto-
kines, RANTES has been demonstrated highly
expressed in atheroma and atherosclerotic disease
[27]. Locati et al’s study also supports through activat-
ing a restricted transcriptional program in human
monocytes, RANTES exerts a novel recruitment amp-
lification loop of leukocytes and promotes monocyte
extravasation and tissue invasion [10]. In this study,
high dose VPA is able to restrict RANTES protein ex-
pression in SAH induced neuro-inflammation.
In summary, the results of this study show that
continuous administration of VPA is safe and effica-
cious in the treatment of vaso-constriction in this ex-
perimental model and is meritorious of further
investigation. Central nervous system administration
of RANTES significantly reversed the anti-vasospasm
effect of VPA in the SAH study. Besides, VPA, at an
optimal dosage, can attenuate ICAM-1 and SAH re-
lated delayed vasospasm through a CCL5 dependent
mechanism.
Conclusions
Despite cerebral vasospasm following SAH has been rec-
ognized for more than half a century, the outcome of
SAH patients revealed devastating, and stood still after
decades of research and treatment on cerebral vaso-
spasm following SAH. Increased evidences revealed
there were multifaceted mechanisms contributing to the
final pathogenesis. These acuminated results arouse interest
to consider the pathogenesis of SAH induced neuro-
inflammation and its effect dictates on the patient’s out-
come. The breakout of brain blood barrier accompanying
SAH may be a critical and complicated pathway underlying
the development and maintenance of subsequent vaso-
constriction. This study shows that administration of VPA,
with its short branch fatty acid, easily penetrates cytoplasm
and diminishes SAH induced ICAM-1 and E-selectin as
well as CD45(+) cells transmigration into vascular wall
in a rodent model of SAH. We suggest that VPA, a
HDAC inhibitor, has other effect than anti-convulsion
and is useful in treating SAH-induced delayed cerebral
ischemia and vasospasm.Abbreviations
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